Clinical Updates in Psoriatic Arthritis

July 27, 2021

Guselkumab, an interleukin-23p19-subunit inhibitor, led to clinically significant and sustained improvements in fatigue through 1 year in patients with active psoriatic arthritis.

July 23, 2021

Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.

July 13, 2021

“This analysis provides information on when clinically meaningful improvements in pain may be expected in patients with psoriatic arthritis receiving tofacitinib or adalimumab, and how baseline pain severity may impact response to tofacitinib, which is of value in clinical practice,” stated investigators.

July 09, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 9, 2021.

July 05, 2021

Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.

July 02, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 2, 2021.

July 01, 2021

The US Food and Drug Administration (FDA) has delayed its decision on upadacitinib (RINVOQ) for the for the treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis.

June 25, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2021.

June 24, 2021

In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.

June 22, 2021

Upadacitinib (UPA) effectively treated patients with psoriatic arthritis (PsA) and axial involvement, a group that is historically more likely to have higher disease burden and more quality-of-life impairments than patients without axial involvement.